Pfizer quickly expands its hemophilia B gene therapy's reach with EU approval

Three months after bagging FDA approval, Pfizer’s hemophilia B gene therapy has been cleared to expand its reach across the pond.

The therapy, which is branded as Beqvez in the U.S., received a conditional marketing authorization from the European Commission under the moniker Durveqtix.